Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Thomas Meyer(1.2%)
Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Thomas Meyer(1.3%)
Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Thomas Meyer(6.3%)
Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Thomas Meyer(8.0%)
Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Thomas Meyer(7.4%)
Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Thomas Meyer(6.3%)
Altamira Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Altium Capital Management, LP EIN:(0%),Altium Growth Fund, LP EIN:(0%)等
Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Thomas Meyer(5.7%)
Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Thomas Meyer(9.2%)
Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Thomas Meyer(8.0%)
Altamira Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Altium Capital Management, LP EIN:(9.9%),Altium Growth Fund, LP EIN:(9.9%)等
Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Thomas Meyer(15.4%)
Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Thomas Meyer(14.4%)
Altamira Therapeutics | SC 13G:超過5%持股股東披露文件-Altium Capital Management, LP EIN:(9.9%),Altium Growth Fund, LP EIN:(9.9%)等
Altamira Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Rosalind Advisors, Inc.(1.2%),Steven Salamon(1.2%)等
Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Sofinnova Capital VII FCPR (“SC VII”) EIN:(0.88%),Sofinnova Partners SAS, a French corporation (“SP SAS”)(0.88%)等
Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Thomas Meyer(27.1%)
Altamira Therapeutics | SC 13G:超過5%持股股東披露文件-Rosalind Advisors, Inc.(8.3%),Steven Salamon(8.3%)等
Altamira Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Morgan Stanley(1.0%),Morgan Stanley Capital Services LLC(1.0%)
Altamira Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-Thomas Meyer(24.4%)
暫無數據